MNOV

Business Context and Reporting Period

Company: MediciNova, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: MediciNova is a development-stage biopharmaceutical company focused on acquiring and developing novel small molecule therapeutics for diseases with unmet medical needs, primarily in the U.S. market. The company relies on strategic alliances, particularly with Japanese pharmaceutical firms, to license product candidates. In December 2009, the company acquired Avigen, Inc., integrating Avigen's ibudilast-based program (AV411) with its own MN-166 program.

Key Pipeline Focus: The company has prioritized two development programs:

• MN-221: For acute exacerbations of asthma and COPD exacerbations (Phase II).
• MN-166/AV411 (Ibudilast): For CNS disorders including Multiple Sclerosis, neuropathic pain, and opioid/methamphetamine addiction (Phase II/IIa).

Key Financial Metrics

Note: The company has no product sales revenue. Operating losses are funded by equity issuances and debt financing.

Material Changes vs. Prior Period

• Debt Financing: In May 2010, the company entered into a $15.0 million senior secured credit facility with Oxford Finance Corporation. This resulted in significant interest expense ($1.8 million in 2010 vs. $0.2 million in 2009) and the incurrence of long-term debt.
• Investment Portfolio: The company exercised its "ARS Put" option in June 2010, redeeming Auction Rate Securities (ARS) at par value and repaying the associated ARS loan. This eliminated the ARS loan liability and the ARS Put asset from the balance sheet. A net impairment charge of $0.8 million was recorded on remaining investment securities in 2010, compared to a net gain of $0.3 million in 2009.
• Operational Efficiency: General and Administrative expenses decreased by $2.2 million (21%) due to the completion of the Avigen transaction costs in 2009 and the absence of management bonus accruals in 2010. R&D expenses decreased by $1.2 million, primarily due to the completion of specific clinical trial phases for MN-221.
• Internal Controls: The company identified a material weakness in internal controls in Q3 2010 related to control overrides by a senior executive. Management reported that this weakness was effectively remediated by December 31, 2010.

Guidance, Outlook, and Risks

Liquidity and Capital Resources:

• The company believes its cash position ($28.3 million at year-end) plus proceeds from a March 2011 public offering (approx. $7.9 million net) will fund operations for at least 12 months.
• Debt Repayment: The company negotiated to repay the $15.0 million Oxford loan in full on April 1, 2011, with the lender waiving an early payment penalty of approximately $437,000.
• Convertible Notes: $28.6 million in convertible notes from the Avigen acquisition mature on June 18, 2011. The company intends to use restricted cash to repay these notes, though holders may elect to convert them to common stock at $6.80 per share.

Outlook and Strategy:

• The company plans to complete enrollment for its pivotal Phase II trial for MN-221 (asthma) in the second half of 2011.
• Development of MN-166/AV411 is paused pending a strategic collaboration to fund further clinical development.
• The company is actively seeking partners to monetize its non-prioritized pipeline assets.

Key Risks:

• Capital Shortfall: Failure to raise additional capital could force significant reductions in R&D and operations.
• Clinical Trial Failure: High risk of failure in clinical trials; delays in enrollment (noted in MN-221 trial) could increase costs and delay regulatory approval.
• Regulatory Approval: No products are approved for commercial sale; FDA approval is uncertain and costly.
• Intellectual Property: Lack of composition of matter patents for MN-166/AV411 and MN-001 exposes the company to competition if competitors develop similar APIs.

Investor Verification Checklist

• Cash Runway: Verify the actual closing of the March 2011 public offering and the net proceeds received to confirm the 12-month liquidity estimate.
• Debt Obligations: Confirm the repayment of the Oxford loan on April 1, 2011, and the status of the $28.6 million convertible notes maturing in June 2011 (conversion vs. cash repayment).
• Clinical Trial Progress: Monitor enrollment rates and completion dates for the MN-221 Phase II trial (MN-221-CL-007), as delays directly impact cash burn and future financing needs.
• Strategic Partnerships: Track progress in securing a strategic partner for the MN-166/AV411 program, as the company has stated it will not fund further significant development without a partner.
• Internal Controls: Review subsequent filings to ensure the remediation of the material weakness in internal controls remains effective.